Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 2-3/2018

22.08.2018

Targeting lipid mediators in cancer biology

verfasst von: Megan L. Sulciner, Allison Gartung, Molly M. Gilligan, Charles N. Serhan, Dipak Panigrahy

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

Bioactive lipids are essential components of human cells and tissues. As discussed in this review, the cancer lipidome is diverse and malleable, with the ability to promote or inhibit cancer pathogenesis. Targeting lipids within the tumor and surrounding microenvironment may be a novel therapeutic approach for treating cancer patients. Additionally, the emergence of a novel super-family of lipid mediators termed specialized pro-resolving mediators (SPMs) has revealed a new role for bioactive lipid mediators in the resolution of inflammation in cancer biology. The role of SPMs in cancer holds great promise in our understanding of cancer pathogenesis and can ultimately be used in future cancer diagnostics and therapy.
Literatur
1.
2.
Krishnamoorthy, S., & Honn, K. V. (2011). Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment. Cancer Metastasis Reviews, 30, 613–618.CrossRefPubMed
3.
4.
5.
Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M., Raetz, C. R. H., Shimizu, T., Spener, F., van Meer, G., Wakelam, M. J. O., & Dennis, E. A. (2009). Update of the LIPID MAPS comprehensive classification system for lipids. Journal of Lipid Research, 50(Suppl), S9–S14.PubMedCentralCrossRefPubMed
6.
Santos, C. R., & Schulze, A. (2012). Lipid metabolism in cancer. The FEBS Journal, 279(15), 2610–2623.CrossRefPubMed
7.
Jiang, N., Zhang, G., Pan, L., Yan, C., Zhang, L., Weng, Y., Wang, W., Chen, X., & Yang, G. (2017). Potential plasma lipid biomarkers in early-stage breast cancer. Biotechnology Letters, 39(11), 1657–1666.CrossRefPubMed
8.
Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. The Journal of Clinical Investigation, 128, 2657–2669.CrossRefPubMed
9.
Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., Lehner, K. A., Bielenberg, D. R., Schmidt, B., Dalli, J., Greene, E. R., Gus-Brautbar, Y., Piwowarski, J., Mammoto, T., Zurakowski, D., Perretti, M., Sukhatme, V. P., Kaipainen, A., Kieran, M. W., Huang, S., & Panigrahy, D. (2018). Resolvins suppress tumor growth and enhance cancer therapy. The Journal of Experimental Medicine, 215(1), 115–140.PubMedCentralCrossRefPubMed
10.
Burr, G. O., & Burr, M. M. (1973). Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutrition Reviews, 31(8), 248–249.PubMed
11.
Nohturfft, A., & Zhang, S. C. (2009). Coordination of lipid metabolism in membrane biogenesis. Annual Review of Cell and Developmental Biology, 25, 539–566.CrossRefPubMed
12.
Singer, S. J., & Nicolson, G. L. (1972). The fluid mosaic model of the structure of cell membranes. Science, 175(4023), 720–731.CrossRefPubMed
13.
Dolce, V., Rita Cappello, A., Lappano, R., & Maggiolini, M. (2011). Glycerophospholipid synthesis as a novel drug target against cancer. Current Molecular Pharmacology, 4(3), 167–175.CrossRefPubMed
14.
Williams, C. D., Whitley, B. M., Hoyo, C., Grant, D. J., Iraggi, J. D., Newman, K. A., Gerber, L., Taylor, L. A., McKeever, M. G., & Freedland, S. J. (2011). A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutrition Research, 31(1), 1–8.CrossRefPubMed
15.
Apte, S. A., Cavazos, D. A., Whelan, K. A., & deGraffenried, L. A. (2013). A low dietary ratio of omega-6 to omega-3 fatty acids may delay progression of prostate cancer. Nutrition and Cancer, 65(4), 556–562.CrossRefPubMed
16.
Pan, J., Cheng, L., Bi, X., Zhang, X., Liu, S., Bai, X., Li, F., & Zhao, A. Z. (2015). Elevation of omega-3 polyunsaturated fatty acids attenuates PTEN-deficiency induced endometrial cancer development through regulation of COX-2 and PGE2 production. Scientific Reports, 5, 14958.PubMedCentralCrossRefPubMed
17.
Brasky, T. M., Darke, A. K., Song, X., Tangen, C. M., Goodman, P. J., Thompson, I. M., Meyskens Jr., F. L., Goodman, G. E., Minasian, L. M., Parnes, H. L., Klein, E. A., & Kristal, A. R. (2013). Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute, 105(15), 1132–1141.PubMedCentralCrossRefPubMed
18.
Zhang, J., Zhang, L., Ye, X., Chen, L., Zhang, L., Gao, Y., Kang, J. X., & Cai, C. (2013). Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 88(5), 355–360.CrossRefPubMed
19.
von Euler, U. S. (1936). On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). The Journal of Physiology, 88(2), 213–234.CrossRef
20.
Samuelsson, B. (1983). From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Bioscience Reports, 3(9), 791–813.CrossRefPubMed
21.
Corey, E. J., Andersen, N. H., Carlson, R. M., Paust, J., Vedejs, E., Vlattas, I., & Winter, R. E. K. (1968). Total synthesis of prostaglandins. Synthesis of the pure dl-E1, -F1-alpha-F1-beta, -A1, and -B1 hormones. Journal of the American Chemical Society, 90(12), 3245–3247.CrossRefPubMed
22.
Corey, E. J., Vlattas, I., Andersen, N. H., & Harding, K. (1968). A new total synthesis of prostaglandins of the E1 and F1 series including 11-epiprostaglandins. Journal of the American Chemical Society, 90(12), 3247–3248.CrossRefPubMed
23.
Tashjian Jr., A. H., et al. (1975). Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells. Nature, 258(5537), 739–741.CrossRefPubMed
24.
Levine, L., Hinkle, P. M., Voelkel, E. F., & Tashjian Jr., A. H. (1972). Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. Biochemical and Biophysical Research Communications, 47(4), 888–896.CrossRefPubMed
25.
Klein, D. C., & Raisz, L. G. (1970). Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology, 86(6), 1436–1440.CrossRefPubMed
26.
Tashjian Jr., A. H., Voelkel, E. F., Goldhaber, P., & Levine, L. (1973). Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglandin-producing fibrosarcoma. Prostaglandins, 3(4), 515–524.CrossRefPubMed
27.
Tashjian Jr., A. H. (1978). Role of prostaglandins in the production of hypercalcemia by tumors. Cancer Research, 38(11 Pt 2), 4138–4141.PubMed
28.
Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology, 231(25), 232–235.
29.
Crofford, L. J. (1997). COX-1 and COX-2 tissue expression: implications and predictions. The Journal of Rheumatology. Supplement, 49, 15–19.PubMed
30.
Hagen, A. A., White, R. P., & Robertson, J. T. (1979). Synthesis of prostaglandins and thromboxane B2 by cerebral arteries. Stroke, 10(3), 306–309.CrossRefPubMed
31.
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107(4), 1183–1188.CrossRefPubMed
32.
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., Levin, B., Godio, L., Patterson, S., Rodriguez-Bigas, M. A., Jester, S. L., King, K. L., Schumacher, M., Abbruzzese, J., DuBois, R. N., Hittelman, W. N., Zimmerman, S., Sherman, J. W., & Kelloff, G. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. The New England Journal of Medicine, 342(26), 1946–1952.CrossRefPubMed
33.
Wang, D., & DuBois, R. N. (2018). Role of prostanoids in gastrointestinal cancer. The Journal of Clinical Investigation, 128, 2732–2742.CrossRefPubMed
34.
Xu, X. C. (2002). COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs, 13(2), 127–137.CrossRefPubMed
35.
36.
Bennett, A., Tacca, M. D., Stamford, I. F., & Zebro, T. (1977). Prostaglandins from tumours of human large bowel. British Journal of Cancer, 35(6), 881–884.PubMedCentralCrossRefPubMed
37.
Bennett, A., Charlier, E. M., McDonald, A., Simpson, J. S., Stamford, I. F., & Zebro, T. (1977). Prostaglandins and breast cancer. Lancet, 2(8039), 624–626.CrossRefPubMed
38.
Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G., Loar, A., Rodabough, R. J., White, E., McTiernan, A., & Women’s Health Initiative. (2003). Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research, 63(18), 6096–6101.PubMed
39.
Reddy, B. S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, K., & Rao, C. V. (2000). Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Research, 60(2), 293–297.PubMed
40.
Thun, M. J., Namboodiri, M. M., & Heath Jr., C. W. (1991). Aspirin use and reduced risk of fatal colon cancer. The New England Journal of Medicine, 325(23), 1593–1596.CrossRefPubMed
41.
Waddell, W. R., & Loughry, R. W. (1983). Sulindac for polyposis of the colon. Journal of Surgical Oncology, 24(1), 83–87.CrossRefPubMed
42.
Whelton, A., & Hamilton, C. W. (1991). Nonsteroidal anti-inflammatory drugs: effects on kidney function. Journal of Clinical Pharmacology, 31(7), 588–598.CrossRefPubMed
43.
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332(7553), 1302–1308.PubMedCentralCrossRefPubMed
44.
MacDonald, T. M., Morant, S. V., Robinson, G. C., Shield, M. J., McGilchrist, M. M., Murray, F. E., & McDevitt, D. G. (1997). Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ, 315(7119), 1333–1337.PubMedCentralCrossRefPubMed
45.
Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., Bertagnolli, M. M., Arber, N., Wittes, J., & for the APC and PreSAP Trial Investigators. (2006). Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114(10), 1028–1035.CrossRefPubMed
46.
Graham, D. J., et al. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet, 365(9458), 475–481.CrossRefPubMed
47.
Couzin, J. (2004). Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science, 306(5695), 384–385.CrossRefPubMed
48.
Gomes, R. N., & Colquhoun, A. (2012). E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro. Lipids in Health and Disease, 11, 171.PubMedCentralCrossRefPubMed
49.
Venza, I., Visalli, M., Fortunato, C., Ruggeri, M., Ratone, S., Caffo, M., Caruso, G., Alafaci, C., Tomasello, F., Teti, D., & Venza, M. (2012). PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation. Epigenetics, 7(11), 1315–1330.PubMedCentralCrossRefPubMed
50.
Larsson, K., Kock, A., Idborg, H., Arsenian Henriksson, M., Martinsson, T., Johnsen, J. I., Korotkova, M., Kogner, P., & Jakobsson, P. J. (2015). COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proceedings of the National Academy of Sciences of the United States of America, 112(26), 8070–8075.PubMedCentralCrossRefPubMed
51.
Li, H. J., Reinhardt, F., Herschman, H. R., & Weinberg, R. A. (2012). Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discovery, 2(9), 840–855.CrossRefPubMed
52.
Van Scott, E. J., & Reinertson, R. P. (1961). The modulating influence of stromal environment on epithelial cells studied in human autotransplants. The Journal of Investigative Dermatology, 36, 109–131.CrossRef
53.
Zhang, A., Wang, M. H., Dong, Z., & Yang, T. (2006). Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. American Journal of Physiology. Renal Physiology, 291(6), F1323–F1331.CrossRefPubMed
54.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3(6), 453–458.CrossRefPubMed
55.
Karnezis, T., Shayan, R., Caesar, C., Roufail, S., Harris, N. C., Ardipradja, K., Zhang, Y. F., Williams, S. P., Farnsworth, R. H., Chai, M. G., Rupasinghe, T. W. T., Tull, D. L., Baldwin, M. E., Sloan, E. K., Fox, S. B., Achen, M. G., & Stacker, S. A. (2012). VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell, 21(2), 181–195.CrossRefPubMed
56.
Wu, J., Zhang, Y., Frilot, N., Kim, J. I., Kim, W. J., & Daaka, Y. (2011). Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. The Journal of Biological Chemistry, 286(39), 33954–33962.PubMedCentralCrossRefPubMed
57.
Li, Z., Zhang, Y., Kim, W. J., & Daaka, Y. (2013). PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene, 32(11), 1408–1415.CrossRefPubMed
58.
Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015). Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology, 149(7), 1884–1895 e4.PubMedCentralCrossRefPubMed
59.
Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., & Chan, K. S. (2015). Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature, 517(7533), 209–213.CrossRefPubMed
60.
Lewis, R. A., & Austen, K. F. (1981). Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature, 293(5828), 103–108.CrossRefPubMed
61.
Lewis, R. A., et al. (1982). Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. Journal of Immunology, 129(4), 1627–1631.
62.
Murata, T., Aritake, K., Matsumoto, S., Kamauchi, S., Nakagawa, T., Hori, M., Momotani, E., Urade, Y., & Ozaki, H. (2011). Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 108(49), 19802–19807.PubMedCentralCrossRefPubMed
63.
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 83(5), 813–819.CrossRefPubMed
64.
Fujita, M., Tohji, C., Honda, Y., Yamamoto, Y., Nakamura, T., Yagami, T., Yamamori, M., & Okamura, N. (2012). Cytotoxicity of 15-deoxy-Delta(12,14)-prostaglandin J(2) through PPARgamma-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. International Journal of Medical Sciences, 9(7), 555–566.PubMedCentralCrossRefPubMed
65.
Hashimoto, K., Ethridge, R. T., & Evers, B. M. (2002). Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. International Journal of Gastrointestinal Cancer, 32(1), 7–22.CrossRefPubMed
66.
Emi, M., & Maeyama, K. (2004). The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Biochemical Pharmacology, 67(7), 1259–1267.CrossRefPubMed
67.
Han, H., Shin, S. W., Seo, C. Y., Kwon, H. C., Han, J. Y., Kim, I. H., Kwak, J. Y., & Park, J. I. (2007). 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. Apoptosis, 12(11), 2101–2114.CrossRefPubMed
68.
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., Ueno, A., Oh-ishi, S., & Narumiya, S. (1997). Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature, 388(6643), 678–682.CrossRefPubMed
69.
Komhoff, M., et al. (1998). Localization of the prostacyclin receptor in human kidney. Kidney International, 54(6), 1899–1908.CrossRefPubMed
70.
Brock, T. G., McNish, R. W., & Peters-Golden, M. (1999). Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. The Journal of Biological Chemistry, 274(17), 11660–11666.CrossRefPubMed
71.
Lim, H., Gupta, R. A., Ma, W. G., Paria, B. C., Moller, D. E., Morrow, J. D., DuBois, R. N., Trzaskos, J. M., & Dey, S. K. (1999). Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes & Development, 13(12), 1561–1574.CrossRef
72.
Forman, B. M., Chen, J., & Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences of the United States of America, 94(9), 4312–4317.PubMedCentralCrossRefPubMed
73.
Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., & DuBois, R. N. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 97(24), 13275–13280.PubMedCentralCrossRefPubMed
74.
Takayama, O., Yamamoto, H., Damdinsuren, B., Sugita, Y., Ngan, C. Y., Xu, X., Tsujino, T., Takemasa, I., Ikeda, M., Sekimoto, M., Matsuura, N., & Monden, M. (2006). Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. British Journal of Cancer, 95(7), 889–895.PubMedCentralCrossRefPubMed
75.
Wu, K. K., & Liou, J. Y. (2009). Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPARdelta --> 14-3-3epsilon pathway. Methods in Molecular Biology, 512, 295–307.CrossRefPubMed
76.
Klein, T., et al. (2015). Expression of prostacyclin-synthase in human breast cancer: negative prognostic factor and protection against cell death in vitro. Mediators of Inflammation, 2015, 864136.PubMedCentralPubMed
77.
Camacho, M., Piñeiro, Z., Alcolea, S., García, J., Balart, J., Terra, X., Avilés-Jurado, F. X., Soler, M., Quer, M., León, X., & Vila, L. (2015). Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy. The Journal of Pathology, 235(1), 125–135.CrossRefPubMed
78.
Li, T., Chen, Y., Zang, W., Geng, N., Ma, S., & Li, X. (2013). Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Current Medical Research and Opinion, 29(8), 889–899.CrossRefPubMed
79.
Sun, J., Zhang, J., Yan, W., Chen, C., Wu, G., Abbasi, S., Pham, B., Lee, S., Cheng, J., Memon, N. B., & Xi, Y. (2014). Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion. International Journal of Cardiology, 176(2), 536–539.CrossRefPubMed
80.
Keith, R. L., Karoor, V., Mozer, A. B., Hudish, T. M., le, M., & Miller, Y. E. (2010). Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression. Lung Cancer, 70(1), 37–42.PubMedCentralCrossRefPubMed
81.
Osawa, T., Ohga, N., Hida, Y., Kitayama, K., Akiyama, K., Onodera, Y., Fujie, M., Shinohara, N., Shindoh, M., Nonomura, K., & Hida, K. (2012). Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner. Cancer Science, 103(6), 1038–1044.CrossRefPubMed
82.
Knezevic, I., Borg, C., & Le Breton, G. C. (1993). Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. The Journal of Biological Chemistry, 268(34), 26011–26017.PubMed
83.
Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., & Narumiya, S. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349(6310), 617–620.CrossRefPubMed
84.
Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W., & Honn, K. V. (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Reviews, 30(3–4), 397–408.CrossRefPubMed
85.
Huang, R. Y., Li, M. Y., Ng, C. S. H., Wan, I. Y. P., Kong, A. W. Y., du, J., Long, X., Underwood, M. J., Mok, T. S. K., & Chen, G. G. (2013). Thromboxane A2 receptor alpha promotes tumor growth through an autoregulatory feedback pathway. Journal of Molecular Cell Biology, 5(6), 380–390.CrossRefPubMed
86.
Huang, R. Y., Li, M. Y., Hsin, M. K. Y., Underwood, M. J., Ma, L. T., Mok, T. S. K., Warner, T. D., & Chen, G. G. (2011). 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene, 30(1), 106–116.CrossRefPubMed
87.
Li, X., & Tai, H. H. (2013). Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells. PLoS One, 8(1), e54073.PubMedCentralCrossRefPubMed
88.
Matsui, Y., Amano, H., Ito, Y., Eshima, K., Suzuki, T., Ogawa, F., Iyoda, A., Satoh, Y., Kato, S., Nakamura, M., Kitasato, H., Narumiya, S., & Majima, M. (2012). Thromboxane A(2) receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells. Cancer Science, 103(4), 700–707.CrossRefPubMed
89.
Shimizu, T. (2009). Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annual Review of Pharmacology and Toxicology, 49, 123–150.CrossRefPubMed
90.
Yang, Y. J., Lee, S. H., Hong, S. J., & Chung, B. C. (1999). Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry, 32(6), 405–409.CrossRefPubMed
91.
Chen, X., Chen, H., Dai, M., Ai, J., Li, Y., Mahon, B., Dai, S., & Deng, Y. (2016). Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget, 7(24), 36622–36631.PubMedCentralPubMed
92.
Morris, P. G., Zhou, X. K., Milne, G. L., Goldstein, D., Hawks, L. C., Dang, C. T., Modi, S., Fornier, M. N., Hudis, C. A., & Dannenberg, A. J. (2013). Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prevention Research (Philadelphia, Pa.), 6(5), 428–436.CrossRef
93.
Kim, S., Taylor, J. A., Milne, G. L., & Sandler, D. P. (2013). Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prevention Research (Philadelphia, Pa.), 6(6), 511–518.CrossRef
94.
Ogretmen, B., & Hannun, Y. A. (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Reviews. Cancer, 4(8), 604–616.CrossRefPubMed
95.
Nava, V. E., Cuvillier, O., Edsall, L. C., Kimura, K., Milstien, S., Gelmann, E. P., & Spiegel, S. (2000). Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Research, 60(16), 4468–4474.PubMed
96.
Lemonnier, L. A., Dillehay, D. L., Vespremi, M. J., Abrams, J., Brody, E., & Schmelz, E. M. (2003). Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Archives of Biochemistry and Biophysics, 419(2), 129–138.CrossRefPubMed
97.
Chen, K., et al. (2014). DMS triggers apoptosis associated with the inhibition of SPHK1/NF-kappaB activation and increase in intracellular Ca2+ concentration in human cancer cells. International Journal of Molecular Medicine, 33(1), 17–24.CrossRefPubMed
98.
Meyers-Needham, M., Lewis, J. A., Gencer, S., Sentelle, R. D., Saddoughi, S. A., Clarke, C. J., Hannun, Y. A., Norell, H., da Palma, T. M., Nishimura, M., Kraveka, J. M., Khavandgar, Z., Murshed, M., Cevik, M. O., & Ogretmen, B. (2012). Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Molecular Cancer Therapeutics, 11(5), 1092–1102.PubMedCentralCrossRefPubMed
99.
Bini, F., Frati, A., Garcia-Gil, M., Battistini, C., Granado, M., Martinesi, M., Mainardi, M., Vannini, E., Luzzati, F., Caleo, M., Peretto, P., Gomez-Muñoz, A., & Meacci, E. (2012). New signalling pathway involved in the anti-proliferative action of vitamin D(3) and its analogues in human neuroblastoma cells. A role for ceramide kinase. Neuropharmacology, 63(4), 524–537.CrossRefPubMed
100.
Kota, V., Szulc, Z. M., & Hama, H. (2012). Identification of C(6)-ceramide-interacting proteins in D6P2T Schwannoma cells. Proteomics, 12(13), 2179–2184.CrossRefPubMed
101.
Sentelle, R. D., Senkal, C. E., Jiang, W., Ponnusamy, S., Gencer, S., Panneer Selvam, S., Ramshesh, V. K., Peterson, Y. K., Lemasters, J. J., Szulc, Z. M., Bielawski, J., & Ogretmen, B. (2012). Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nature Chemical Biology, 8(10), 831–838.PubMedCentralCrossRefPubMed
102.
Huwiler, A., Brunner, J., Hummel, R., Vervoordeldonk, M., Stabel, S., van den Bosch, H., & Pfeilschifter, J. (1996). Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America, 93(14), 6959–6963.PubMedCentralCrossRefPubMed
103.
Zhang, Y., Yao, B., Delikat, S., Bayoumy, S., Lin, X. H., Basu, S., McGinley, M., Chan-Hui, P. Y., Lichenstein, H., & Kolesnick, R. (1997). Kinase suppressor of Ras is ceramide-activated protein kinase. Cell, 89(1), 63–72.CrossRefPubMed
104.
Saddoughi, S. A., & Ogretmen, B. (2013). Diverse functions of ceramide in cancer cell death and proliferation. Advances in Cancer Research, 117, 37–58.CrossRefPubMed
105.
Selzner, M., Bielawska, A., Morse, M. A., Rüdiger, H. A., Sindram, D., Hannun, Y. A., & Clavien, P. A. (2001). Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Research, 61(3), 1233–1240.PubMed
106.
Jiang, Y., DiVittore, N. A., Kaiser, J. M., Shanmugavelandy, S. S., Fritz, J. L., Heakal, Y., Tagaram, H. R. S., Cheng, H., Cabot, M. C., Staveley-O’Carroll, K. F., Tran, M. A., Fox, T. E., Barth, B. M., & Kester, M. (2011). Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biology & Therapy, 12(7), 574–585.CrossRef
107.
Ryland, L. K., Doshi, U. A., Shanmugavelandy, S. S., Fox, T. E., Aliaga, C., Broeg, K., Baab, K. T., Young, M., Khan, O., Haakenson, J. K., Jarbadan, N. R., Liao, J., Wang, H. G., Feith, D. J., Loughran Jr, T. P., Liu, X., & Kester, M. (2013). C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia. PLoS One, 8(12), e84648.PubMedCentralCrossRefPubMed
108.
Watters, R. J., et al. (2012). Development and use of ceramide nanoliposomes in cancer. Methods in Enzymology, 508, 89–108.CrossRefPubMed
109.
Garcia, J. G., et al. (2001). Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. The Journal of Clinical Investigation, 108(5), 689–701.PubMedCentralCrossRefPubMed
110.
Singleton, P. A., Dudek, S. M., Chiang, E. T., & Garcia, J. G. N. (2005). Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. The FASEB Journal, 19(12), 1646–1656.CrossRefPubMed
111.
Watson, C., Long, J. S., Orange, C., Tannahill, C. L., Mallon, E., McGlynn, L. M., Pyne, S., Pyne, N. J., & Edwards, J. (2010). High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. The American Journal of Pathology, 177(5), 2205–2215.PubMedCentralCrossRefPubMed
112.
Lim, K. G., Tonelli, F., Li, Z., Lu, X., Bittman, R., Pyne, S., & Pyne, N. J. (2011). FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. The Journal of Biological Chemistry, 286(21), 18633–18640.PubMedCentralCrossRefPubMed
113.
Ruckhaberle, E., et al. (2008). Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Research and Treatment, 112(1), 41–52.CrossRefPubMed
114.
Watson, D. G., Tonelli, F., Alossaimi, M., Williamson, L., Chan, E., Gorshkova, I., Berdyshev, E., Bittman, R., Pyne, N. J., & Pyne, S. (2013). The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cellular Signalling, 25(4), 1011–1017.PubMedCentralCrossRefPubMed
115.
116.
Kawamori, T., Osta, W., Johnson, K. R., Pettus, B. J., Bielawski, J., Tanaka, T., Wargovich, M. J., Reddy, B. S., Hannun, Y. A., Obeid, L. M., & Zhou, D. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. The FASEB Journal, 20(2), 386–388.CrossRefPubMed
117.
Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1–4), 27–36.CrossRef
118.
Nagahashi, M., Ramachandran, S., Kim, E. Y., Allegood, J. C., Rashid, O. M., Yamada, A., Zhao, R., Milstien, S., Zhou, H., Spiegel, S., & Takabe, K. (2012). Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Research, 72(3), 726–735.PubMedCentralCrossRefPubMed
119.
Hwang, H., Kim, E. K., Park, J., Suh, P. G., & Cho, Y. K. (2014). RhoA and Rac1 play independent roles in lysophosphatidic acid-induced ovarian cancer chemotaxis. Integrative Biology (Camb), 6(3), 267–276.CrossRef
120.
Tsujiuchi, T., Hirane, M., Dong, Y., & Fukushima, N. (2014). Diverse effects of LPA receptors on cell motile activities of cancer cells. Journal of Receptor and Signal Transduction Research, 34(3), 149–153.CrossRefPubMed
121.
Willier, S., Butt, E., & Grunewald, T. G. (2013). Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biology of the Cell, 105(8), 317–333.CrossRefPubMed
122.
Matayoshi, S., et al. (2013). Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells. International Journal of Oncology, 42(5), 1560–1568.PubMedCentralCrossRefPubMed
123.
Yang, D., et al. (2013). Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2. Oncology Letters, 5(3), 1048–1052.PubMedCentralCrossRefPubMed
124.
Oda, S. K., Strauch, P., Fujiwara, Y., al-Shami, A., Oravecz, T., Tigyi, G., Pelanda, R., & Torres, R. M. (2013). Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunology Research, 1(4), 245–255.PubMedCentralCrossRefPubMed
125.
Ogden, C. L., et al. Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS Data Brief, 2015(219), 1–8.
126.
Ma, Y., Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y., & Qin, H. (2013). Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One, 8(1), e53916.PubMedCentralCrossRefPubMed
127.
Wang, F., & Xu, Y. (2014). Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. International Journal of Cancer, 135(7), 1673–1686.CrossRefPubMed
128.
Chen, Y., Wang, X., Wang, J., Yan, Z., & Luo, J. (2012). Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. European Journal of Cancer, 48(14), 2137–2145.CrossRefPubMed
129.
Dougan, M. M., Hankinson, S. E., Vivo, I. D., Tworoger, S. S., Glynn, R. J., & Michels, K. B. (2015). Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. International Journal of Cancer, 137(3), 625–637.PubMedCentralCrossRefPubMed
130.
Srinivas, G. V., Namala, S., Ananthaneni, A., Puneeth, H. K., & Devi, B. S. (2013). Evaluation and correlation of serum lipid profile in oral and gastrointestinal cancer patients. Journal of International Oral Health, 5(6), 72–77.PubMed
131.
Martin, L. J., et al. (2015). Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. Journal of the National Cancer Institute, 107(5).
132.
Ulmer, H., et al. (2009). Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer, 101(7), 1202–1206.PubMedCentralCrossRefPubMed
133.
Esposito, K., Chiodini, P., Capuano, A., Bellastella, G., Maiorino, M. I., & Giugliano, D. (2014). Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine, 45(1), 28–36.CrossRefPubMed
134.
Zhang, C., Yu, L., Xu, T., Hao, Y., Zhang, X., Liu, Z., Xiao, Y., Wang, X., & Zeng, Q. (2013). Association of dyslipidemia with renal cell carcinoma: a 1ratio2 matched case-control study. PLoS One, 8(3), e59796.PubMedCentralCrossRefPubMed
135.
Saito, K., Arai, E., Maekawa, K., Ishikawa, M., Fujimoto, H., Taguchi, R., Matsumoto, K., Kanai, Y., & Saito, Y. (2016). Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma. Scientific Reports, 6, 28932.PubMedCentralCrossRefPubMed
136.
Nelson, E. R., Wardell, S. E., Jasper, J. S., Park, S., Suchindran, S., Howe, M. K., Carver, N. J., Pillai, R. V., Sullivan, P. M., Sondhi, V., Umetani, M., Geradts, J., & McDonnell, D. P. (2013). 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science, 342(6162), 1094–1098.PubMedCentralCrossRefPubMed
137.
Li, P., Zhang, H., Chen, J., Shi, Y., Cai, J., Yang, J., & Wu, Y. (2014). Association between dietary antioxidant vitamins intake/blood level and risk of gastric cancer. International Journal of Cancer, 135(6), 1444–1453.CrossRefPubMed
138.
Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., Karp, D. D., Lieber, M. M., Walther, P. J., Klotz, L., Parsons, J. K., Chin, J. L., Darke, A. K., Lippman, S. M., Goodman, G. E., Meyskens, F. L., & Baker, L. H. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306(14), 1549–1556.PubMedCentralCrossRefPubMed
139.
Sayin, V. I., et al. (2014). Antioxidants accelerate lung cancer progression in mice. Science Translational Medicine, 6(221), 221ra15.CrossRefPubMed
140.
Juanola-Falgarona, M., Salas-Salvadó, J., Martínez-González, M. Á., Corella, D., Estruch, R., Ros, E., Fitó, M., Arós, F., Gómez-Gracia, E., Fiol, M., Lapetra, J., Basora, J., Lamuela-Raventós, R. M., Serra-Majem, L., Pintó, X., Muñoz, M. Á., Ruiz-Gutiérrez, V., Fernández-Ballart, J., & Bulló, M. (2014). Dietary intake of vitamin K is inversely associated with mortality risk. The Journal of Nutrition, 144(5), 743–750.CrossRefPubMed
141.
Faust, P. L., & Kovacs, W. J. (2014). Cholesterol biosynthesis and ER stress in peroxisome deficiency. Biochimie, 98, 75–85.CrossRefPubMed
142.
Bui, D. T., Nicolas, J., Maksimenko, A., Desmaële, D., & Couvreur, P. (2014). Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. Chemical Communications (Camb), 50(40), 5336–5338.CrossRef
143.
Desmaele, D., Gref, R., & Couvreur, P. (2012). Squalenoylation: a generic platform for nanoparticular drug delivery. Journal of Controlled Release, 161(2), 609–618.CrossRefPubMed
144.
Couvreur, P., Stella, B., Reddy, L. H., Hillaireau, H., Dubernet, C., Desmaële, D., Lepêtre-Mouelhi, S., Rocco, F., Dereuddre-Bosquet, N., Clayette, P., Rosilio, V., Marsaud, V., Renoir, J. M., & Cattel, L. (2006). Squalenoyl nanomedicines as potential therapeutics. Nano Letters, 6(11), 2544–2548.CrossRefPubMed
145.
Maksimenko, A., Alami, M., Zouhiri, F., Brion, J. D., Pruvost, A., Mougin, J., Hamze, A., Boissenot, T., Provot, O., Desmaële, D., & Couvreur, P. (2014). Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS Nano, 8(3), 2018–2032.PubMedCentralCrossRefPubMed
146.
Tan, L. T. (2013). Pharmaceutical agents from filamentous marine cyanobacteria. Drug Discovery Today, 18(17–18), 863–871.CrossRefPubMed
147.
Chiorazzi, A., Nicolini, G., Canta, A., Oggioni, N., Rigolio, R., Cossa, G., Lombardi, R., Roglio, I., Cervellini, I., Lauria, G., Melcangi, R. C., Bianchi, R., Crippa, D., & Cavaletti, G. (2009). Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiology of Disease, 35(2), 270–277.CrossRefPubMed
148.
Guzman, E. A., et al. (2017). Inhibition of IL-8 secretion on BxPC-3 and MIA PaCa-2 cells and induction of cytotoxicity in pancreatic cancer cells with marine natural products. Anti-Cancer Drugs, 28(2), 153–160.CrossRefPubMed
149.
Chou, T. C., Zhang, X. G., Harris, C. R., Kuduk, S. D., Balog, A., Savin, K. A., Bertino, J. R., & Danishefsky, S. J. (1998). Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America, 95(26), 15798–15802.PubMedCentralCrossRefPubMed
150.
Issa, M. E., Hall, S. R., Dupuis, S. N., Graham, C. L., Jakeman, D. L., & Goralski, K. B. (2014). Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Anti-Cancer Drugs, 25(3), 255–269.CrossRefPubMed
151.
Choi, E. S., Jung, J. Y., Lee, J. S., Park, J. H., Cho, N. P., & Cho, S. D. (2013). Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Letters, 328(1), 65–72.CrossRefPubMed
152.
Arthur, J. C., Perez-Chanona, E., Muhlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T. J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., Rhodes, J. M., Stintzi, A., Simpson, K. W., Hansen, J. J., Keku, T. O., Fodor, A. A., & Jobin, C. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338(6103), 120–123.PubMedCentralCrossRefPubMed
153.
154.
Serhan, C. N., & Chiang, N. (2013). Resolution phase lipid mediators of inflammation: agonists of resolution. Current Opinion in Pharmacology, 13(4), 632–640.PubMedCentralCrossRefPubMed
155.
Serhan, C. N. (2007). Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annual Review of Immunology, 25, 101–137.CrossRefPubMed
156.
Serhan, C. N., et al. (2011). Novel anti-inflammatory—pro-resolving mediators and their receptors. Current Topics in Medicinal Chemistry, 11(6), 629–647.PubMedCentralCrossRefPubMed
157.
Serhan, C. N., & Savill, J. (2005). Resolution of inflammation: the beginning programs the end. Nature Immunology, 6(12), 1191–1197.CrossRefPubMed
158.
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., & Serhan, C. N. (2012). Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. The American Journal of Pathology, 180(5), 2018–2027.PubMedCentralCrossRefPubMed
159.
Sun, Y. P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S. P., Petasis, N. A., & Serhan, C. N. (2007). Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. The Journal of Biological Chemistry, 282(13), 9323–9334.CrossRefPubMed
160.
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R. L. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. The Journal of Experimental Medicine, 196(8), 1025–1037.PubMedCentralCrossRefPubMed
161.
Serhan, C. N. (2005). Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 73(3–4), 141–162.CrossRefPubMed
162.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.CrossRefPubMed
163.
164.
165.
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., Siostrzonek, P., Sinnaeve, P., Fonseca, F., Nicolau, J., Gotcheva, N., Genest, J., Yong, H., Urina-Triana, M., Milicic, D., Cifkova, R., Vettus, R., Koenig, W., Anker, S. D., Manolis, A. J., Wyss, F., Forster, T., Sigurdsson, A., Pais, P., Fucili, A., Ogawa, H., Shimokawa, H., Veze, I., Petrauskiene, B., Salvador, L., Kastelein, J., Cornel, J. H., Klemsdal, T. O., Medina, F., Budaj, A., Vida-Simiti, L., Kobalava, Z., Otasevic, P., Pella, D., Lainscak, M., Seung, K. B., Commerford, P., Dellborg, M., Donath, M., Hwang, J. J., Kultursay, H., Flather, M., Ballantyne, C., Bilazarian, S., Chang, W., East, C., Everett, B., Forgosh, L., Glynn, R., Harris, B., Libby, P., Ligueros, M., Thuren, T., Bohula, E., Charmarthi, B., Cheng, S., Chou, S., Danik, J., McMahon, G., Maron, B., Ning, M. M., Olenchock, B., Pande, R., Perlstein, T., Pradhan, A., Rost, N., Singhal, A., Taqueti, V., Wei, N., Burris, H., Cioffi, A., Dalseg, A. M., Ghosh, N., Gralow, J., Mayer, T., Rugo, H., Fowler, V., Limaye, A. P., Cosgrove, S., Levine, D., Lopes, R., Scott, J., Thuren, T., Ligueros, M., Hilkert, R., Tamesby, G., Mickel, C., Manning, B., Woelcke, J., Tan, M., Manfreda, S., Ponce, T., Kam, J., Saini, R., Banker, K., Salko, T., Nandy, P., Tawfik, R., O'Neil, G., Manne, S., Jirvankar, P., Lal, S., Nema, D., Jose, J., Collins, R., Bailey, K., Blumenthal, R., Colhoun, H., Gersh, B., & Glynn, R. J. (2017). Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 390(10105), 1833–1842.CrossRefPubMed
166.
Ye, Y., Scheff, N. N., Bernabé, D., Salvo, E., Ono, K., Liu, C., Veeramachaneni, R., Viet, C. T., Viet, D. T., Dolan, J. C., & Schmidt, B. L. (2018). Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. Neuropharmacology, 139, 182–193.CrossRefPubMed
167.
Shepelin, D., Korzinkin, M., Vanyushina, A., Aliper, A., Borisov, N., Vasilov, R., Zhukov, N., Sokov, D., Prassolov, V., Gaifullin, N., Zhavoronkov, A., Bhullar, B., & Buzdin, A. (2016). Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human. Oncotarget, 7(1), 656–670.CrossRefPubMed
168.
Zhong, X., Lee, H. N., & Surh, Y. J. (2018). RvD1 inhibits TNFalpha-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. Biochemical and Biophysical Research Communications, 496(2), 316–323.CrossRefPubMed
169.
Halder, R. C., et al. (2015). Curcuminoids and omega-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon gamma production. Frontiers in Physiology, 6, 129.PubMedCentralCrossRefPubMed
170.
Kuang, H., et al. (2016). Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-kappaB activity. Oncology Reports, 35(1), 307–317.CrossRefPubMed
171.
Prevete, N., Liotti, F., Illiano, A., Amoresano, A., Pucci, P., de Paulis, A., & Melillo, R. M. (2017). Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. Oncoimmunology, 6(4), e1293213.PubMedCentralCrossRefPubMed
172.
Lee, H. J., Park, M. K., Lee, E. J., & Lee, C. H. (2013). Resolvin D1 inhibits TGF-beta1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. The International Journal of Biochemistry & Cell Biology, 45(12), 2801–2807.CrossRef
173.
Liu, Y., Yuan, X., Li, W., Cao, Q., & Shu, Y. (2016). Aspirin-triggered resolvin D1 inhibits TGF-beta1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely linked to oxidative stress. International Journal of Molecular Medicine, 38(4), 1235–1242.CrossRefPubMed
174.
Simoes, R. L., et al. (2017). Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression. International Journal of Cancer, 140(2), 346–357.CrossRefPubMed
175.
Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., Ye, D., Hoidal, J., Wu, P., & Chen, X. (2010). Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics, 9(8), 2164–2174.CrossRefPubMed
176.
Stenke, L., Edenius, C., Samuelsson, J., & Lindgren, J. A. (1991). Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood, 78(11), 2989–2995.PubMed
177.
Wang, C., Xiao, M., Liu, X., Ni, C., Liu, J., Erben, U., & Qin, Z. (2013). IFN-gamma-mediated downregulation of LXA4 is necessary for the maintenance of nonresolving inflammation and papilloma persistence. Cancer Research, 73(6), 1742–1751.CrossRefPubMed
178.
Wang, Z., Cheng, Q., Tang, K., Sun, Y., Zhang, K., Zhang, Y., Luo, S., Zhang, H., Ye, D., & Huang, B. (2015). Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer Letters, 364(2), 118–124.CrossRefPubMed
179.
Chandrasekharan, J. A., Huang, X. M., Hwang, A. C., & Sharma-Walia, N. (2016). Altering the anti-inflammatory lipoxin microenvironment: a new insight into Kaposi’s sarcoma-associated herpesvirus pathogenesis. Journal of Virology, 90(24), 11020–11031.PubMedCentralCrossRefPubMed
180.
Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. The Journal of Experimental Medicine, 206(1), 15–23.PubMedCentralCrossRefPubMed
181.
Dalli, J., Vlasakov, I., Riley, I. R., Rodriguez, A. R., Spur, B. W., Petasis, N. A., Chiang, N., & Serhan, C. N. (2016). Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 113(43), 12232–12237.PubMedCentralCrossRefPubMed
Metadaten
Titel
Targeting lipid mediators in cancer biology
verfasst von
Megan L. Sulciner
Allison Gartung
Molly M. Gilligan
Charles N. Serhan
Dipak Panigrahy
Publikationsdatum
22.08.2018
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2-3/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-018-9754-9

Weitere Artikel der Ausgabe 2-3/2018

Cancer and Metastasis Reviews 2-3/2018 Zur Ausgabe

OriginalPaper

Eicosanoid signaling in carcinogenesis of colorectal cancer

OriginalPaper

Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation

OriginalPaper

Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications

OriginalPaper

The role of lipid signaling in the progression of malignant melanoma

OriginalPaper

Targeting the enzymes involved in arachidonic acid metabolism to improve radiotherapy

OriginalPaper

Role of autotaxin in cancer stem cells

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise